ArticleInternational journal of women's dermatology2024
Botulinum toxin treatment of refractory vaginismus: a prospective study.
Article in International journal of women's dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Botulinum Toxin for Refractory Vaginismus: A Therapeutic Evaluation of a Rare and Under-Researched Condition.JBRA assisted reproduction · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vaginismus is a common sexual dysfunction. A few studies have indicated that botulinum neurotoxin type A (BoNTA) can help treat refractory vaginismus by alleviating muscle tension. However, such studies did not use standardized methodology and BoNTA dosage. Objective: The aim is to evaluate the efficacy of intravaginal BoNTA injection in treating refractory vaginismus. Also, we intended to assess the effectiveness and safety of modest doses, that is, 100 to 200 IU of submucosal BoNTA injections. Methods: A prospective study was conducted in an outpatient surgical center over 18 months. Twenty patients aged 29 to 49 years (mean, 30.9 years) with refractory vaginismus were enrolled. All patients had been sexually inactive at the time of treatment. All participants had received various treatments such as psychotherapy, vaginal dilatator therapy, muscle relaxants, and lubricants with no relief. A dose of 100 to 200 IU of BoNTA was injected submucosally in the lateral sides of the bulbospongiosus, pubococcygeus, and puborectalis muscle areas. The patients were followed over 4 months posttreatment. Results: Nineteen patients (95%) achieved satisfactory intercourse by the end of the 4-month follow-up period. A repeat BoNTA injection was not required as there were no recurrences. None of the participants reported adverse effects. Limitations: A small sample size and lack of a control group. Conclusion: Injecting submucosally modest BoNTA doses is an effective and safe treatment for refractory vaginismus. When conventional therapies fail, BoNTA can be used to lessen muscle contraction, alleviate pain, and facilitate dilator treatments. Our standardized protocol, which involves a careful submucosal injection technique, can minimize risks and make the procedure easy to perform for daily practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.